GlassScriptPhysician profile
Peter Karlsberg
NPI 1063560605
$1,667.99
in general payments reported to CMS, 2019-2025
17 companies · $3.99 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $225 · 2021: $195 · 2022: $303 · 2023: $367 · 2024: $280 · 2025: $3.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.41 |
| Education | $154.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $256.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $236.65 | 2019-2023 | |
| Abbvie INC. | $225.37 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $196.80 | 2021-2024 | Ilumya |
| Galderma Laboratories, L.P. | $137.11 | 2022 | |
| Merz North America, INC. | $105.36 | 2019-2023 | Xeomin |
| Journey Medical Corporation | $103.36 | 2020-2024 | |
| Pfizer INC. | $81.11 | 2019-2023 | |
| Ucb, INC. | $67.81 | 2021 | |
| Amgen INC. | $59.70 | 2023-2024 | Otezla |
| Genzyme Corporation | $48.42 | 2019-2022 | |
| Biofrontera INC. | $46.27 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $31.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.71 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.47 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $15.30 | 2019 | |
| Organon LLC | $3.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Karlsberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.